FILE 'HOME' ENTERED AT 20:34:47 ON 16 DEC 2004

=> e .biotech

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE The EXPAND command is used to look at the index in a file which has an index. This file does not have an index.

=> file .biotech
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 20:35:04 ON 16 DEC 2004

FILE 'CAPLUS' ENTERED AT 20:35:04 ON 16 DEC 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 20:35:04 ON 16 DEC 2004 Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 20:35:04 ON 16 DEC 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'AGRICOLA' ENTERED AT 20:35:04 ON 16 DEC 2004

FILE 'SCISEARCH' ENTERED AT 20:35:04 ON 16 DEC 2004 Copyright (c) 2004 The Thomson Corporation.

=> s salt?1 or "sodium chloride"
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'SALT?1'
The truncation symbol ? may be used only at the end of a search term. To specify a variable character within a word use '!', e.g., 'wom!n' to search for both 'woman' and 'women'. Enter "HELP TRUNCATION" at an arrow prompt (=>) for more information.

=> s L1 and L2 L3 476729 L1 AND L2

=> e encapsulated

ENCAPSULATEA/BI 1 ENCAPSULATEAD/BI E21 E3 75832 --> ENCAPSULATED/BI ENCAPSULATEDC/BI E41 ENCAPSULATEDIN/BI 2 E5 2 ENCAPSULATEDIN/BI
2 ENCAPSULATEDS/BI
1 ENCAPSULATEED/BI
3 ENCAPSULATER/BI
1628 ENCAPSULATES/BI
1 ENCAPSULATESD/BI E6 E7 E8 E9 E10 ENCAPSULATETHE/BI 1 E11 1 ENCAPSULATIC/BI E12

```
=> s e3
         75832 ENCAPSULATED/BI
T.4
=> s e9
         1628 ENCAPSULATES/BI
L<sub>5</sub>
=> s L3 and L4 or L5
          2481 L3 AND L4 OR L5
=> e probiotic
             1
                   PROBIOTCIS/BI
                   PROBIOTECH/BI
E2
             3
E3
         10198 --> PROBIOTIC/BI
E4
           17
                  PROBIOTICA/BI
E5
            12
                  PROBIOTICAL/BI
E6
            17
                  PROBIOTICALLY/BI
E7
                  PROBIOTICAND/BI
            1
            2 PROBIOTICAS/BI
1 PROBIOTICBIFIDOBACTERIUM/BI
1 PROBIOTICDID/BI
E.8
E.9
E10
E11
             1
                  PROBIOTICELE/BI
                  PROBIOTICHE/BI
E12
             1
=> s e3
         10198 PROBIOTIC/BI
L7
=> s L6 and L7
            11 L6 AND L7
=> d ab bib L8 1-11
L8
     ANSWER 1 OF 11
                        MEDLINE on STN
     Bifidobacterium cells were encapsulated in a mixed gel composed
AΒ
     of alginate, pectin, and whey proteins. Two kinds of capsules
     were obtained: gel beads without membranes and gel beads with two
     membranes formed by the transacylation reaction. In vitro studies were
     carried out to determine the effects of simulated gastric pH and bile
     salts on the survival of free and encapsulated Bifidobacterium
     bifidum. The protective effects of gel beads without membranes and gel
     beads coated with two membranes formed by the transacylation reaction were
     evaluated. After 1 h in an acidic solution (pH 2.5), the free-cell counts
     decreased by 4.75 log units, compared with a <1-log decrease for entrapped
     cells. The free cells did not survive after 2 h of incubation at pH 2.5,
     while immobilized-cell counts decreased by about 2 log units. After
     incubation (1 or 3 h) in 2 and 4% bile salt solutions, the
     bifidobacterium mortality level for membrane-free gel beads (4 to 7 log
     units) was higher than that for free cells (2 to 3 log units). However,
     counts of bifidobacteria immobilized in membrane-coated gel beads
     decreased by <2 log units. Cell encapsulation in membrane-coated protein-
     polysaccharide gel beads could be used to increase the survival of
     healthy probiotic bacteria during their transit through the
     gastrointestinal tract.
ΔN
     2003547850
                    MEDLINE
DN
     PubMed ID: 14627286
ΤI
     Protection of bifidobacteria encapsulated in
    polysaccharide-protein gel beads against gastric juice and bile.
     Guerin Daniel; Vuillemard Jean-Christophe; Subirade Muriel
ΑU
     Centre de Recherche en Sciences et Technologie du Lait STELA, Faculte des
CS
     Sciences de l'Agriculture et de l'Alimentation, Universite Laval, Quebec,
     Canada G1K 7P4.
SO
    Journal of food protection, (2003 Nov) 66 (11) 2076-84.
    Journal code: 7703944. ISSN: 0362-028X.
CY
     United States
    Journal; Article; (JOURNAL ARTICLE)
DТ
```

- LA English
- FS Priority Journals
- EM 200401
- ED Entered STN: 20031121

Last Updated on STN: 20040109 Entered Medline: 20040108

- L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
- The probiotics, Lactobacillus acidophilus 547, Bifidobacterium bifidum AB ATCC 1994, and Lactobacillus casei 01, were encapsulated into uncoated calcium alginate beads and the same beads were coated with three types of material, chitosan, sodium alginate, and poly-L-lysine in combination with alginate. The thickness of the alginate beads increased with the addition of coating materials. No differences were detectable in the bead strength by texture anal. or in the thickness of the beads with different types of coating materials by transmission electron microscopy. The survivability of three probiotics in uncoated beads, coated beads, and as free cells (unencapsulated) was conducted in 0.6% bile **salt** solution and simulated gastric juice (pH 1.55) followed by incubation in simulated intestinal juice with and without 0.6% bile salt. Chitosan-coated alginate beads provided the best protection for L. acidophilus and L. casei in all treatments. bifidum did not survive the acidic conditions of gastric juice even when encapsulated in coated beads.
- AN 2004:483609 CAPLUS
- TI The influence of coating materials on some properties of alginate beads and survivability of microencapsulated **probiotic** bacteria
- AU Krasaekoopt, Wunwisa; Bhandari, Bhesh; Deeth, Hilton
- CS School of Land and Food Sciences, The University of Queensland, St. Lucia, 4072, Australia
- SO International Dairy Journal (2004), 14(8), 737-743 CODEN: IDAJE6; ISSN: 0958-6946
- PB Elsevier Science B.V
- DT Journal
- LA English
- RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
- An edible matrix composition that has a chewable texture and that contains at AB least one encapsulated component is obtained by admixing at least one plasticizer, and a ground, free-flowing particulate mixture which comprises at least one fat, at least one starch, and at least one sugar which have been mixed and heated without substantially gelatinizing the starch. A chewable texture is obtained rather than a hard, glassy matrix because the starch is substantially ungelatinized. However, a flavorful product is obtained without destroying a heat sensitive encapsulant because the starch is admixed with ingredients comprising fat or oil and sugar and the mixture is heated to develop flavor at high temps. prior to admixing with the heat sensitive encapsulant. The encapsulated component may be at least one biol. active component, pharmaceutical component, nutraceutical component, or microorganism. In preferred embodiments, the free-flowing mixture is obtained by grinding cookies. free-flowing mixture, such as ground cookies and the plasticizer, such as oil and water are mixed with an encapsulant to obtain a formable dough or crumbly mass. The formable dough is shaped or formed into pieces or pellets and dried to a shelf-stable moisture content.
- AN 2004:327158 CAPLUS
- DN 140:320335
- TI Encapsulation of components into edible products
- IN Van Lengerich, Bernhard H.
- PA General Mills, Inc., USA
- SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 233,443. CODEN: USXXAM

```
DT
     Patent
     English
TιA
FAN.CNT 2
     PATENT NO.
                        KIND DATE
                                             APPLICATION NO.
                                                                       DATE
                          ----
                                  _____
                                               -----
     US 6723358 B1 20040420 US 2001-673983
WO 9948372 A1 19990930 WO 1999-US4267
PΙ
                                               US 2001-673983
                                                                        20010201
                                                                        19990323
         W: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD,
              RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,
              NE, SN, TD, TG
         RW: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
              DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
              MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
              TR, TT, UA, UG, US, UZ, VN, YU, ZW
     NO 2000004784 A
US 1998-79060P P
US 1998-103700P P
US 1998-109696P P
                               20000925
                                             NO 2000-4784
PRAI US 1998-79060P
                                 19980323
                                 19981009
                                 19981124
     US 1999-233443 A2
WO 1999-US4267 W
                                  19990120
                                 19990323
RE.CNT 136
               THERE ARE 136 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
L8
     ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
     Bifidobacterium cells were encapsulated in a mixed gel composed
     of alginate, pectin, and whey proteins. Two kinds of capsules
     were obtained: gel beads without membranes and gel beads with two
     membranes formed by the transacylation reaction. In vitro studies were
     carried out to determine the effects of simulated gastric pH and bile salts on
     the survival of free and encapsulated Bifidobacterium bifidum.
     The protective effects of gel beads without membranes and gel beads coated
     with two membranes formed by the transacylation reaction were evaluated.
     After 1 h in an acidic solution (pH 2.5), the free-cell counts decreased by
     4.75 log units, compared with a < 1-log decrease for entrapped cells.
     free cells did not survive after 2 h of incubation at pH 2.5, while
     immobilized-cell counts decreased by about 2 log units. After incubation
     (1 or 3 h) in 2 and 4% bile salt solns., the bifidobacterium
     mortality level for membrane-free gel beads (4 to 7 log units) was higher
     than that for free cells (2 to 3 log units). However, counts of
     bifidobacteria immobilized in membrane-coated gel beads decreased by <2
     log units. Cell encapsulation in membrane-coated protein-
     polysaccharide gel beads could be used to increase the survival of
     healthy probiotic bacteria during their transit through the
     gastrointestinal tract.
```

- AN 2003:958928 CAPLUS
- DN 140:252345
- TI Protection of bifidobacteria encapsulated in polysaccharide-protein gel beads against gastric juice and bile

AU Guerin, Daniel; Vuillemard, Jean-Christophe; Subirade, Muriel

- CS Centre de Recherche en Sciences et Technologie du Lait STELA, Faculte des Sciences de l'Agriculture et de l'Alimentation, Universite Laval, QC, G1K 7P4, Can.
- SO Journal of Food Protection (2003), 66(11), 2076-2084 CODEN: JFPRDR; ISSN: 0362-028X
- PB International Association for Food Protection
- DT Journal
- LA English
- RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
- AB The present invention relates to novel strains capable of producing

conjugated linoleic acid (CLA). The strains include Bifidobacterium breve CBG-C2, Bifidobacterium pseudocatenulatum CBG-C4 and Enterococcus faecium CBG-C5. The strains are excellent in producing CLA and are able to secret the produced CLA to a medium or to accumulate in the cells. Also, the strains show strong resistance to antibiotics and acids such as stomach acid or bile **salt**. A composition comprising the strain according tot he present invention is prepared in the form a capsule comprising the strain according to the present invention and CLA **encapsulated** in a coating material comprising water soluble polysaccharides and may be used in functional foods and medicaments.

AN 2003:837265 CAPLUS

DN 139:322387

TI Conjugated linoleic acid producing Bifidobacteria and Enterococcus strains and their use to manufacture probiotics, food additives and pharmaceuticals

IN Kim, So-Mi; Oh, Deok-Kun; Baek, Dae-Heoun; Sin, Hong-Sig; Park, Si-Ho; Lee, Yu-Jin; Um, Soo-Jong; Rho, Young-Soy; Park, Jong-Sup; Kim, Dong-Myong

PA Chebigen Inc., S. Korea SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

```
PATENT NO.
                                             KIND
                                                           DATE
                                                                                 APPLICATION NO.
                                                                                                                            DATE
                                             ____
                                                                                 -----
                                                           -----
PΙ
         WO 2003087344
                                               A1
                                                           20031023
                                                                               WO 2003-KR742
                                                                                                                          20030412
                W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                       AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BG, BR, BI, BZ, CA, CII, CR, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
                RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
                        BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
         KR 2003081180
                                              Α
                                                           20031017
                                                                                 KR 2003-23164
                                                                                                                            20030412
PRAI KR 2002-20057
                                               Α
                                                           20020412
```

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

AB A method for delivering a medicament or agent to an individual using a chewing gum-like product, specifically a coated gum-like product is provided. The medicament or agent is present within the coating that surrounds a center comprising a gum base. By chewing the product, the medicament or agent is released from the product. Continuing to chew the product creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system. For example, an acetaminophen coated product contained (a) gum base center (1 g), and (b) coating (1 g) made of acetaminophen 80.0 g, encapsulated aspartame 20.0 g, aspartame 50.0 g, salt flour 2.5 g, dextrose 643.5 g, and flavor 4.0 g.

AN 2003:203183 CAPLUS

DN 138:243278

TI Over-coated chewing gum formulations

IN Ream, Ronald L.; Greenberg, Michael J.; Wokas, William J.; Corriveau, Christine L.

PA Wm. Wrigley Jr., Co., USA

SO U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. 6,355,265. CODEN: USXXCO

```
DT
       Patent
LA
       English
FAN.CNT 19
       PATENT NO.
                              KIND DATE
                                                        APPLICATION NO.
                                                                                        DATE
                                _ _ _ _
                                          -----
                                                          _______
ΡI
      US 2003049208
                                A1
                                          20030313
                                                         US 2001-992122
                                                                                        20011113
       US 6773716
                                 B2
                                          20040810
       CA 2431856
                                 AA
                                          19980604
                                                          CA 1996-2431856
                                                                                        19961127
                                                      WO 1999-US29742
       WO 2000035296
                                 A1
                                          20000622
                                                                                        19991214
            W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
                 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
                 AZ, BY, KG, KZ, MD, RU, TJ, TM
            RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
                 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      US 6355265
                                 B1
                                          20020312 US 2000-510878
                                                                                        20000223
      EP 1347746
                                  A1
                                          20031001
                                                         EP 2001-953503
                                                                                        20010717
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
      US 2004180007
                            A1
                                          20040916
                                                       US 2003-743609
                                                                                        20031222
PRAI US 1999-286818
                                A2
                                          19990406
      WO 1999-US29742 W
US 2000-510878 A2
CA 1996-2271889 A3
WO 1996-US18977 A2
US 1998-112389P P
US 1999-308972 A2
US 1999-389211 A2
                                          19991214
                                          20000223
                                         19961127
                                         19961127
                                         19981215
                                         19990527
      US 1999-389211
                                A2
                                         19990902
      US 2000-671552
                                B1
                                         20000927
      WO 2001-US22360
                                 W
                                         20010717
RE.CNT 268
                 THERE ARE 268 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

L8 ANSWER 7 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. or

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- AB The probiotics, Lactobacillus acidophilus 547, Bifidobacterium bifidum ATCC 1994, and Lactobacillus casei 01, were encapsulated into uncoated calcium alginate beads and the same beads were coated with three types of material, chitosan, sodium alginate, and poly-L-lysine in combination with alginate. The thickness of the alginate beads increased with the addition of coating materials. No differences were detectable in the bead strength by texture analysis or in the thickness of the beads with different types of coating materials by transmission electron microscopy. The survivability of three probiotics in uncoated beads, coated beads, and as free cells (unencapsulated) was conducted in 0.6% bile salt solution and simulated gastric juice (pH 1.55) followed by incubation in simulated intestinal juice with and without 0.6%bile salt. Chitosan-coated alginate beads provided the best protection for L. acidophilus and L. casei in all treatments. However, B. bifidum did not survive the acidic conditions of gastric juice even when encapsulated in coated heads. Copyright 2004 Elsevier Ltd. All rights reserved.
- AN 2004:351158 BIOSIS
- DN PREV200400352159
- TI The influence of coating materials on some properties of alginate beads and survivability of microencapsulated **probiotic** bacteria.
- AU Krasaekoopt, Wunwisa; Bhandari, Bhesh [Reprint Author]; Deeth, Hilton
- CS Sch Land and Food Sci, Univ Queensland, St Lucia, Qld, 4072, Australia b.bhandari@uq.edu.au
- SO International Dairy Journal, (August 2004) Vol. 14, No. 8, pp. 737-743. print.

ISSN: 0958-6946.

- DT Article
- LA English
- ED Entered STN: 26 Aug 2004 Last Updated on STN: 26 Aug 2004
- L8 ANSWER 8 OF 11 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
- AΒ Bifidobacterium cells were encapsulated in a mixed gel composed of alginate, pectin, and whey proteins. Two kinds of capsules were obtained: gel beads without membranes and gel beads with two membranes formed by the transacylation reaction. In vitro studies were carried out to determine the effects of simulated gastric pH and bile salts on the survival of free and encapsulated Bifidobacterium bifidum. The protective effects of gel beads without membranes and gel beads coated with two membranes formed by the transacylation reaction were evaluated. After 1 h in an acidic solution (pH 2.5), the free-cell counts decreased by 4.75 log units, compared with a <1-log decrease for entrapped The free cells did not survive after 2 h of incubation at pH 2.5, while immobilized-cell counts decreased by about 2 log units. After incubation (1 or 3 h) in 2 and 4% bile salt solutions, the bifidobacterium mortality level for membrane-free gel beads (4 to 7 log units) was higher than that for free cells (2 to 3 log units). However, counts of bifidobacteria immobilized in membrane-coated gel beads decreased by <2 log units. Cell encapsulation in membrane-coated proteinpolysaccharide gel beads could be used to increase the survival of healthy probiotic bacteria during their transit through the gastrointestinal tract.
- AN 2004:8007 BIOSIS
- DN PREV200400008580
- TI Protection of bifidobacteria encapsulated in polysaccharide-protein gel beads against gastric juice and bile.
- AU Guerin, Daniel; Vuillemard, Jean-Christophe [Reprint Author]; Subirade,
  Muriel
- CS Centre de Recherche en Sciences et Technologie du Lait STELA, Faculte des Sciences de l'Agriculture et de l'Alimentation, Universite Laval, Sainte-Foy, PQ, G1K 7P4, Canada jean-christophe.vuillemard@aln.ulaval.ca
- Journal of Food Protection, (November 2003) Vol. 66, No. 11, pp. 2076-2084. print.
  ISSN: 0362-028X (ISSN print).
- DT Article
- LA English
- ED Entered STN: 17 Dec 2003 Last Updated on STN: 17 Dec 2003
- L8 ANSWER 9 OF 11 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
- A modified method using calcium alginate for the microencapsulation of AΒ probiotic bacteria is reported in this study. Incorporation of Hi-Maize starch (a prebiotic) improved encapsulation of viable bacteria as compared to when the bacteria were encapsulated without the starch. Inclusion of glycerol (a cryo-protectant) with alginate mix increased the survival of bacteria when frozen at - 20°C. The acidification kinetics of encapsulated bacteria showed that the rate of acid produced was lower than that of free cultures. The encapsulated bacteria, however, did not demonstrate a significant increase in survival when subjected to in vitro high acid and bile salt conditions. A preliminary study was carried out in order to monitor the effects of encapsulation on the survival of Lactobacillus acidophilus and Bifidobacterium spp. in yoghurt over a period of 8 weeks. This study showed that the survival of encapsulated cultures of L. acidophilus and Bifidobacterium spp. showed a decline in viable count of about 0.5log over a period of 8 weeks while there was a decline of

about 1log in cultures which were incorporated as free cells in yoghurt. The encapsulation method used in this study did not result in uniform bead size, and hence additional experiments need to be designed using uniform bead size in order to assess the role of different encapsulation parameters, such as bead size and alginate concentration, in providing protection to the bacteria. (C) 2000 Elsevier Science B.V.

AN 2000416452 EMBASE

- TI Encapsulation of **probiotic** bacteria with alginate-starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt.
- AU Sultana K.; Godward G.; Reynolds N.; Arumugaswamy R.; Peiris P.; Kailasapathy K.
- CS K. Kailasapathy, Centre for Advanced Food Research, University of Western Sydney, Richmond, NSW 2753, Australia. k.kailasapathy@uws.edu.au
- SO International Journal of Food Microbiology, (5 Dec 2000) 62/1-2 (47-55). Refs: 25

ISSN: 0168-1605 CODEN: IJFMDD

- PUI S 0168-1605(00)00380-9
- CY Netherlands
- DT Journal; Article
- FS 004 Microbiology
- LA English
- SL English
- L8 ANSWER 10 OF 11 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
- The probiotics, Lactobacillus acidophilus 547, Bifidobacterium bifidum AΒ ATCC 1994, and Lactobacillus casei 01, were encapsulated into uncoated calcium alginate beads and the same beads were coated with three types of material, chitosan, sodium alginate, and poly-L-lysine in combination with alginate. The thickness of the alginate beads increased with the addition of coating materials. No differences were detectable in the bead strength by texture analysis or in the thickness of the beads with different types of coating materials by transmission electron microscopy. The survivability of three probiotics in uncoated beads, coated beads, and as free cells (unencapsulated) was conducted in 0.6% bile salt solution and simulated gastric juice (pH 1.55) followed by incubation in simulated intestinal juice with and without 0.6% bile salt. Chitosan-coated alginate beads provided the best protection for L. acidophilus and L. casei in all treatments. However, B. bifidum did not survive the acidic conditions of gastric juice even when encapsulated in coated heads. (C) 2004 Elsevier Ltd. All rights reserved.
- AN 2004:622077 SCISEARCH
- GA The Genuine Article (R) Number: 833WP
- TI The influence of coating materials on some properties of alginate beads and survivability of microencapsulated **probiotic** bacteria
- AU Krasaekoopt W; Bhandari B (Reprint); Deeth H
- CS Univ Queensland, Sch Land & Food Sci, St Lucia, Qld 4072, Australia (Reprint)
- CYA Australia
- SO INTERNATIONAL DAIRY JOURNAL, (AUG 2004) Vol. 14, No. 8, pp. 737-743. Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND. ISSN: 0958-6946.
- DT Article; Journal
- LA English
- REC Reference Count: 26
  \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*
- L8 ANSWER 11 OF 11 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
- AB Bifidobacterium cells were **encapsulated** in a mixed gel composed of **alginate**, pectin, and whey proteins. Two kinds of

capsules were obtained: gel beads without membranes and gel beads with two membranes formed by the transacylation reaction. In vitro studies were carried out to determine the effects of simulated gastric pH and bile salts on the survival of free and encapsulated Bifidobacterium bifidum. The protective effects of gel beads without membranes and gel beads coated with two membranes formed by the transacylation reaction were evaluated. After 1 h in an acidic solution (pH 2.5), the free-cell counts decreased by 4.75 log units, compared with a <1-log decrease for entrapped cells. The free cells did not survive after 2 h of incubation at pH 2.5, while immobilized-cell counts decreased by about 2 log units. After incubation (1 or 3 h) in 2 and 4% bile salt solutions, the bifidobacterium mortality level for membrane-free gel beads (4 to 7 log units) was higher than that for free cells (2 to 3 log units). However, counts of bifidobacteria immobilized in membrane-coated get beads decreased by <2 log units. Cell encapsulation in membrane-coated proteinpolysaccharide gel beads could be used to increase the survival of healthy probiotic bacteria during their transit through the gastrointestinal tract.

AN 2003:1004011 SCISEARCH

GA The Genuine Article (R) Number: 741YX

TI Protection of bifidobacteria encapsulated in polysaccharide-protein gel beads against gastric juice and bile

AU Guerin D; Vuillemard J C (Reprint); Subirade M

CS Univ Laval, Fac Sci Agr & Alimentat, Ctr Rech Sci & Technol, Lait STELA, Laval, PQ G1K 7P4, Canada (Reprint)

CYA Canada

SO JOURNAL OF FOOD PROTECTION, (NOV 2003) Vol. 66, No. 11, pp. 2076-2084. Publisher: INT ASSOC FOOD PROTECTION, 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA.

ISSN: 0362-028X. Article; Journal

LA English

REC Reference Count: 54

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

## => d his

DT

L2

(FILE 'HOME' ENTERED AT 20:34:47 ON 16 DEC 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, AGRICOLA, SCISEARCH' ENTERED AT 20:35:04 ON 16 DEC 2004

L1 2966245 S MONOVALENT OR SODIUM OR POTASSIUM OR POLYSACCHARIDE AND (ALGI

1256224 S SALT OR "SODIUM CHLORIDE"

L3 476729 S L1 AND L2

E ENCAPSULATED

L4 75832 S E3

L5 1628 S E9

L6 2481 S L3 AND L4 OR L5

E PROBIOTIC

L7 10198 S E3

L8 11 S L6 AND L7

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L10	2	"5389532".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 18:59
L11	2	"6365148".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:05
L12	22	"4956295"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:12
L13	0	"4956295.pn."	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:05
L14	2	"4927763".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:14
L15	786057	alginate monvalent sodium postassium polysaccharide\$1	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:15
L16	317778	capsule\$2 encapsulat\$2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:16
L17	1200793	salt\$ "sodium chloride" 2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:19
L18	491045	L15 and L17	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:19
L19	4152853	survival resistance block combat fight	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:21
L20	874	simulated NEAR gastric	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:21
L21	116948	L18 and L16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:21

L22	408	L19 and L20	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:22
L23	284	L21 and L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:22
L24	220866	bacteria	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:23
L25	869	probiotic and L24	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:23
L26	6	L23 and L25	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:33
L27	11272	lactobacillus bifidobacterium	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:33
L28	9	"L35" and L27	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:37
L29	3653674	extend increase enhance lengthen prolong	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:39
L30	52316	shelf Near1 life	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:39
L31	30813	L29 and L30	US-PGPUB; USPAT; EPO; JPO;	OR	OFF	2004/12/16 19:39
L32	110	L25 and L31	DERWENT US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:59
L33	102025	"424"/\$.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 19:59

L34	65	l32 and L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:00
L35	359	L25 and L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:00
L36	0	424/184.1.ccls and L25	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:00
L37	2	424/184.1.ccls. and L32	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:02
L38	7	L34 and alginate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:02
L39	31	L35 and alginate	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/12/16 20:02